Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_94ff2d78578d95d1e8d3a2233c76188d |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-136 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2500-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2500-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-4706 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K8-365 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6813 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-502 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5023 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5026 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61Q19-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5008 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6876 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6881 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6875 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61Q19-02 |
filingDate |
2015-09-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5b05e504c4eafe26af3a35e747d0a223 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6ee258fe044a4897e8fe7310f000cb63 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_51970177c503e0c7756d01f87c0cd0ad |
publicationDate |
2016-03-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
WO-2016040246-A1 |
titleOfInvention |
Method of making a skin care composition |
abstract |
A method of making a skin composition that includes an effective amount of skin care agent selected to inhibit HMGB1 stimulation of human melanocytes. The method includes determining the level of high-mobility group protein B1 (HMGB1), messenger RNA associated with the expression and/or regulation of HMGB1 (HMGB1 mRNA), and/or micro-RNA associated with the expression and/or regulation of HMGB1 (HMGB1 miRNA) present in the test sample, and identifying the test agent as a skin tone agent when there is no increase in HMGB1 level, a downregulation in transcription of HMGB1 mRNA, and/or an upregulation of HMGB1 miRNA. The method also includes identifying a test agent as a skin tone agent when the test agent inhibits or prevents an increase in melanocyte dendricity and/or body size caused by HMGB1, and incorporating the skin tone agent in a dermatologically acceptable carrier. |
isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2016178944-A1 |
priorityDate |
2014-09-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |